Most Recent
Reckitt Benckiser has filed an appeal against GlaxoSmithKline, after a judge found the consumer goods giant misled consumers with claims that Nurofen was a more effective pain killer than its rival’s Panadol and ordered it to pay all of GlaxoSmithKline’s legal bill.
Lawyers running a class action against Murray Goulburn want access to evidence that the dairy cooperative's trust consulted with a QC about possible claims against its law firm, Herbert Smith Freehills.
The Australian Securities and Investments Commission has lodged a case in Federal Court against Rio Tinto, its former CEO and former CFO over allegedly misleading market statements it made about the reserves of a recent $4 billion acquisition, a controversy that has already landed the mining giant in hot water with regulators in the UK and US.
Australia's consumer regulator has taken Woolworths to court, saying it made deceptive claims to consumers about the biodegradability of its 'eco' line of picnic products.
A judge has ordered the former head of collapsed vocational training organisation Australian Careers Network to foot the legal bill of Nationwide News, likely to exceed $ 1 million, for a defamation case he brought and lost.
A judge has called for a referee to look at Maurice Blackburn's fees for running a shareholder class action against QBE Insurance that settled late last year for $133 million.
Patent lawyer and inventor Todd Martin will get two days in court to challenge the Australian Patent Office's decision to reject his innovation for failing the manner of manufacture test, one of two closely watched appeals challenging computer software patent rejections.
Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca's cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.
Reckitt Benckiser has been ordered to pay all of GlaxoSmithKline's legal bill after a judge found the drug giant misled consumers with claims that Nurofen was a more effective pain killer than its rival's Panadol.
The Australian Competition and Consumer Commission said it is well positioned to investigate competition in the financial sector, in response to a recent report calling for a dedicated financial services competition regulator.